Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman, Timothy P. Rolph
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 161

Showing 1-25 of 161 citing articles:

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1262-1271
Open Access | Times Cited: 249
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1475-1486
Open Access | Times Cited: 146
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 129
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A. Harrison, Juan P. Frías, Guy Neff, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 12, pp. 1080-1093
Closed Access | Times Cited: 85
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Deepak L. Bhatt, Harold Bays, Michael Miller, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1782-1792
Open Access | Times Cited: 51
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells
Cegui Hu, Wen Qiao, Xiang Li, et al.
Cell Metabolism (2024) Vol. 36, Iss. 3, pp. 630-647.e8
Closed Access | Times Cited: 20
Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
Julia M. Fraile, Soumya Palliyil, Caroline J. Barelle, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 3997-4009
Open Access | Times Cited: 96
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
Rohit Loomba, Eric Lawitz, Juan P. Frías, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 120-132
Closed Access | Times Cited: 65
A gut-derived hormone suppresses sugar appetite and regulates food choice in Drosophila
Alina Malita, Olga I. Kubrak, Takashi Koyama, et al.
Nature Metabolism (2022) Vol. 4, Iss. 11, pp. 1532-1550
Open Access | Times Cited: 59
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
JHEP Reports (2022) Vol. 5, Iss. 1, pp. 100563-100563
Open Access | Times Cited: 53
Prolonged breastfeeding protects from obesity by hypothalamic action of hepatic FGF21
Verónica Pena-León, Cintia Folgueira, Silvia Barja-Fernández, et al.
Nature Metabolism (2022) Vol. 4, Iss. 7, pp. 901-917
Open Access | Times Cited: 43
Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications
Leigang Jin, Ranyao Yang, Leiluo Geng, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 359-382
Open Access | Times Cited: 40
The role of FGF21 and its analogs on liver associated diseases
Kimia Falamarzi, Mahdi Malekpour, Mobin Fallah Tafti, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 38
A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future
Emily Holz, Martine Darwish, Devin B. Tesar, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 600-600
Open Access | Times Cited: 28
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas, et al.
Clinical Gastroenterology and Hepatology (2024)
Open Access | Times Cited: 13
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
Marija Branković, Marija Dukić, Tijana Gmizić, et al.
Diagnostics (2024) Vol. 14, Iss. 2, pp. 229-229
Open Access | Times Cited: 9
New approaches to triglyceride reduction: Is there any hope left?
Annalisa Filtz, Siddhant Parihar, G Greenberg, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100648-100648
Open Access | Times Cited: 7
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease
Wah‐Kheong Chan, Soek‐Siam Tan, Siew‐Pheng Chan, et al.
Journal of Gastroenterology and Hepatology (2022) Vol. 37, Iss. 5, pp. 795-811
Open Access | Times Cited: 34
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 31
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Zhihai Huang, Hung Wen Lin, Quanguang Zhang, et al.
Nutrients (2022) Vol. 14, Iss. 20, pp. 4298-4298
Open Access | Times Cited: 30
Phytochemicals from the Cocoa Shell Modulate Mitochondrial Function, Lipid and Glucose Metabolism in Hepatocytes via Activation of FGF21/ERK, AKT, and mTOR Pathways
Miguel Rebollo‐Hernanz, Yolanda Aguilera, Maria A. Martín‐Cabrejas, et al.
Antioxidants (2022) Vol. 11, Iss. 1, pp. 136-136
Open Access | Times Cited: 29
Distinct AMPK-Mediated FAS/HSL Pathway Is Implicated in the Alleviating Effect of Nuciferine on Obesity and Hepatic Steatosis in HFD-Fed Mice
Hanyuan Xu, Xiaorui Lyu, Xiaonan Guo, et al.
Nutrients (2022) Vol. 14, Iss. 9, pp. 1898-1898
Open Access | Times Cited: 28
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook
Alberto Nascè, Karim Gariani, François R. Jornayvaz, et al.
Antioxidants (2022) Vol. 11, Iss. 6, pp. 1131-1131
Open Access | Times Cited: 28
Intermittent fasting—the future treatment in NASH patients?
Iulia Minciună, Suchira Gallage, Mathias Heikenwälder, et al.
Hepatology (2023) Vol. 78, Iss. 4, pp. 1290-1305
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top